Oblique Back-illumination Microscopy Jerome Mertz

8
Oblique Back-illumination Microscopy Jerome Mertz June 15, 2012

description

Oblique Back-illumination Microscopy Jerome Mertz. June 15, 2012. Oblique Back-illumination Microscopy (OBM ) Breakthrough imaging allows DIC-like images in thick samples. 600μm field-of-view with 6.5μm resolution 240μm field-of-view with 2.5μm resolution - PowerPoint PPT Presentation

Transcript of Oblique Back-illumination Microscopy Jerome Mertz

PowerPoint Presentation

Oblique Back-illumination MicroscopyJerome MertzJune 15, 20121600m field-of-view with 6.5m resolution240m field-of-view with 2.5m resolutionNo labeling or contrast requiredVideo rate

Oblique Back-illumination Microscopy (OBM)Breakthrough imaging allows DIC-like images in thick samplesOBM offers superior imaging and high clinical impactin a simple, robust, and cost-effective platformSuperior imaging capabilities with high clinical impactExquisite high resolution phase images (DIC-like) of in vivo tissue morphology Simultaneous phase and amplitude microscopy with tissue imaging depth of 60-100m improves diagnostic imaging in thick tissueapplications in endoscopyWorks at video rate with a standard cameraSimple, robust, cost effective, and safeAdd-on to current microscopes or endomicroscopes, with no moving partsNoninvasive, no tissue labeling requiredIlluminated using LEDs rather than expensive and unsafe lasersBoth research and clinical applicationsare possible with OBM$3B US Microscope Market in 2011 with 6% CAGR through 20151Several Established Players: Leica, Carl Zeiss, Olympus, etc790 Potential Target Labs in US2GI Endoscopy> 10 MM Procedures / yearColorectal, Gall, EsophagealBlood flow analysis in plastic / reconstructive surgery>1MM surgeries per year Bladder imagingResearch ApplicationsClinical Applications3Jon Groberg, Dane Leone, CFA, Danaher: BEC is the key to continued success, Macquarie (USA) Equities Research, 16 Aug 2011Source: http://www.lltechimaging.com/Source: Mauna Kea Investor Presentation, published June 2011

Colorectal ScreeningsGI screening offers a compelling opportunity for OBM

Barretts Esophagus

3.1 MM colorectal screenings in US annuallyHigh percentage of biopsied polyps are benignStrong market opportunity for technologies that aid in biopsy site determination> 1 MM screenings in US annuallyAmerican Gastroenterological Assoc. recently increased recommended screening schedule for high risk patients85% mortality rate for Esophageal cancer (BE increases cancer risk)OBM combines high resolution imaging with tissue depth, wide field-of-view and video capabilitiesOBMOCT1Confocal fluorescenceEndomicroscopy2Technology2.5 / 6.53.51 - 3.5 Lateral Resolution (m)61.83 - 8Axial Resolution (m)0 - 801005 - 100Imaging Depth(m)240 / 6001.5 x 1.5 mm(scanning)240 / 400Field of View(m)1. Optical Coherence Tomography data points based on lltech Light-CT2. Confocal Laser Endomicroscopy data points based on various CellVizio models 17.5112(200 optional)Frame Rate (Hz)Rigid endoscope market exceeds $500M annually; Karl Storz is the market leaderMarket Size (2010):$529M WW, 4% CAGR$176M US, 4% CAGRLaparoscopic, Hysteroscopic usesSource: Rigid Endoscopes - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017, Global Data, 31 May 2011In vivo Imaging TechnologiesTechnologyCompanyProductUnit CostTarget AreasOCTSt. Jude MedicalIlumien (OCT + FFR)UnknownStent Placement, Vulnerable Plaque IDOPSLekam Medical LtdCytoscanUnknownMicrocirculation (possibly no sales since 2004)LIFSpectraSciencewavSTATUnknownColorectal/esophageal CancerOpticalSpectroscopyGuided TherapeuticsLuViva $18,5001 Cervical Cancer CirculationImagingNovadaqPinPoint$75,0004Lung, Colectomy, Lap Chole, MISCLEMauna Kea Technologies (via Leica)Cellvizio$160,0002Barret's, Colorectal, CholeMultispectralImagingMela SciencesMelaFind$35,0003Melanoma1. Thomson Reuters Streetevents, Edited Transcript: GTHP.OB-Q4 2011 Guided Therapeutics Inc. Earnings Conference Call, 29 March 2012, 3:00PM GMT2. Source: Mauna Kea Investor Presentation, published June 20113. Josh Jennings, M.D., Denis Kelleher, Ian Sanderson, Doug Schenkel, Mela Sciences Initiating with Outperform (1), Cowen and Company, 23 May 20124. Matt Miksic, Sachin Kulharni, Young Li, Novadaq: Overweight, PiperJaffray, Company Note, 16 April 2012